JP7496818B2 - エキソソーム標的化二重特異性抗体 - Google Patents

エキソソーム標的化二重特異性抗体 Download PDF

Info

Publication number
JP7496818B2
JP7496818B2 JP2021521141A JP2021521141A JP7496818B2 JP 7496818 B2 JP7496818 B2 JP 7496818B2 JP 2021521141 A JP2021521141 A JP 2021521141A JP 2021521141 A JP2021521141 A JP 2021521141A JP 7496818 B2 JP7496818 B2 JP 7496818B2
Authority
JP
Japan
Prior art keywords
seq
antibody
bispecific antibody
antigen
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021521141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512734A (ja
JP2022512734A5 (cg-RX-API-DMAC7.html
Inventor
ロビンソン、マシュー、ケイ.
モリン、マイケル、ジョン
Original Assignee
イムノーム、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イムノーム、インコーポレイテッド filed Critical イムノーム、インコーポレイテッド
Publication of JP2022512734A publication Critical patent/JP2022512734A/ja
Publication of JP2022512734A5 publication Critical patent/JP2022512734A5/ja
Priority to JP2024086669A priority Critical patent/JP2024123004A/ja
Application granted granted Critical
Publication of JP7496818B2 publication Critical patent/JP7496818B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021521141A 2018-10-17 2019-10-17 エキソソーム標的化二重特異性抗体 Active JP7496818B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024086669A JP2024123004A (ja) 2018-10-17 2024-05-28 エキソソーム標的化二重特異性抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862746862P 2018-10-17 2018-10-17
US62/746,862 2018-10-17
PCT/US2019/056698 WO2020081786A1 (en) 2018-10-17 2019-10-17 Exosome-targeting bispecific antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024086669A Division JP2024123004A (ja) 2018-10-17 2024-05-28 エキソソーム標的化二重特異性抗体

Publications (3)

Publication Number Publication Date
JP2022512734A JP2022512734A (ja) 2022-02-07
JP2022512734A5 JP2022512734A5 (cg-RX-API-DMAC7.html) 2022-10-17
JP7496818B2 true JP7496818B2 (ja) 2024-06-07

Family

ID=70284767

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021521141A Active JP7496818B2 (ja) 2018-10-17 2019-10-17 エキソソーム標的化二重特異性抗体
JP2024086669A Abandoned JP2024123004A (ja) 2018-10-17 2024-05-28 エキソソーム標的化二重特異性抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024086669A Abandoned JP2024123004A (ja) 2018-10-17 2024-05-28 エキソソーム標的化二重特異性抗体

Country Status (12)

Country Link
US (1) US20210347895A1 (cg-RX-API-DMAC7.html)
EP (1) EP3866851A4 (cg-RX-API-DMAC7.html)
JP (2) JP7496818B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210091714A (cg-RX-API-DMAC7.html)
CN (1) CN113423425A (cg-RX-API-DMAC7.html)
AU (1) AU2019359877A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021007469A2 (cg-RX-API-DMAC7.html)
CA (1) CA3116560A1 (cg-RX-API-DMAC7.html)
IL (1) IL282355A (cg-RX-API-DMAC7.html)
MX (1) MX2021004036A (cg-RX-API-DMAC7.html)
SG (1) SG11202103812RA (cg-RX-API-DMAC7.html)
WO (1) WO2020081786A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021006431A2 (pt) * 2018-10-02 2021-07-27 Immunome, Inc. anticorpos direcionados a epn1
CN113754771A (zh) * 2020-06-02 2021-12-07 三生国健药业(上海)股份有限公司 一种抗pdl1×egfr的双特异性抗体
CN114354913B (zh) * 2021-12-31 2024-07-19 厦门大学 一种外泌体pd-l1糖基化检测方法
CN114990129B (zh) * 2022-05-11 2023-02-03 北京贝来生物科技有限公司 表达αPDL1:Fc融合蛋白的间充质干细胞的制备及应用
WO2023225613A2 (en) * 2022-05-18 2023-11-23 Immunome, Inc. Combination anti-epn1 and anti-pd-l1 antibody therapies
EP4630966A2 (en) * 2022-12-09 2025-10-15 The Regents of the University of California Intelligent design and engineering of proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136820A2 (en) 2016-02-06 2017-08-10 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
WO2017162890A1 (en) 2016-03-25 2017-09-28 Biomunex Pharmaceuticals Binding molecules to cd38 and pd-l1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356367B (es) * 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
SG11201704056XA (en) * 2014-11-20 2017-06-29 Hoffmann La Roche Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
GB201500319D0 (en) * 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
RU2018105846A (ru) * 2015-07-29 2019-08-28 Новартис Аг Комбинация антагониста pd-1 с ингибитором egfr
WO2017087280A1 (en) * 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN108250302A (zh) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多功能蛋白质

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136820A2 (en) 2016-02-06 2017-08-10 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
WO2017162890A1 (en) 2016-03-25 2017-09-28 Biomunex Pharmaceuticals Binding molecules to cd38 and pd-l1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Zumaquero, E. et al.,"Exosomes from human lymphoblastoid B cells express enzymatically active CD38 that is associated with signaling complexes containing CD81, Hsc-70 and Lyn",Exp. Cell Res.,2010年,Vol. 316,pp. 2692-2706

Also Published As

Publication number Publication date
AU2019359877A1 (en) 2021-05-20
WO2020081786A1 (en) 2020-04-23
JP2022512734A (ja) 2022-02-07
JP2024123004A (ja) 2024-09-10
SG11202103812RA (en) 2021-05-28
CN113423425A (zh) 2021-09-21
CA3116560A1 (en) 2020-04-23
EP3866851A4 (en) 2022-11-02
KR20210091714A (ko) 2021-07-22
MX2021004036A (es) 2021-08-24
EP3866851A1 (en) 2021-08-25
BR112021007469A2 (pt) 2021-08-10
US20210347895A1 (en) 2021-11-11
IL282355A (en) 2021-05-31

Similar Documents

Publication Publication Date Title
JP2024123004A (ja) エキソソーム標的化二重特異性抗体
JP7685771B2 (ja) 二重特異性抗体およびその使用
TWI631136B (zh) 單特異性及雙特異性抗igf-1r及抗erbb3抗體
WO2020043184A1 (zh) 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
BR112021002032A2 (pt) construtos de anticorpos para cldn18.2 e cd3
AU2019201141B2 (en) Novel antibody binding to TFPI and composition comprising the same
WO2019206281A1 (zh) 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
BR112019022751A2 (pt) composição farmacêutica compreendendo construtos de anticorpos biespecíficos para armazenamento e administração melhorados
BR112019016104A2 (pt) composição farmacêutica de baixo ph compreendendo construtos de anticorpo que empregam células t
CN106132990A (zh) 抗mcam抗体和相关使用方法
WO2022100590A1 (zh) 针对密蛋白18a2的adcc增强型人源化抗体及其应用
JP2022511096A5 (cg-RX-API-DMAC7.html)
JP2018530540A (ja) 巨細胞動脈炎、リウマチ性多発筋痛症又は高安動脈炎の処置又は予防のための抗mcam抗体の使用
CA3208455A1 (en) Novel anti-gremlin1 antibodies
CN117916272A (zh) 多特异性抗原结合蛋白
JP2025531328A (ja) キメラ抗原受容体t細胞の可逆的制御
WO2022068894A1 (zh) 同时靶向pd-l1和vegf的双功能分子及其医药用途
JP7753401B2 (ja) ヒト化抗clec-1a抗体及びその抗原結合断片及びそのミメティック
WO2022127066A9 (zh) 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途
HK40060740A (en) Exosome-targeting bispecific antibodies
TW202540199A (zh) 靶向her2及her3之雙特異性四價抗體
TW202613175A (zh) Cdh3結合蛋白及其用途
TW202540198A (zh) 雙特異性抗體樣蛋白以及彼之製造及使用方法
TW202534086A (zh) 抗psca抗體及其用途
WO2025193962A1 (en) Anti-vegf and pd-1 bispecific antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240229

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240425

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240528

R150 Certificate of patent or registration of utility model

Ref document number: 7496818

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150